Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-TPP
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
18F-TPP (4-[18F]fluorophenyltriphenylphosphonium) is a radiopharmaceutical small molecule developed by Massachusetts General Hospital. It functions as a PET imaging tracer that targets the mitochondrial membrane potential in cardiac tissue. By accumulating in cardiac cells based on the electrochemical gradient across mitochondrial membranes, it allows for the visualization of myocardial viability and electrical activity. This imaging agent is primarily being evaluated in Phase 2 clinical trials to guide catheter ablation procedures in patients with recurrent ventricular arrhythmia, particularly those with scar-mediated ventricular tachycardia following myocardial infarction, by helping clinicians identify the precise sources of arrhythmia.
- Other names
- 4-[18F]fluorophenyltriphenylphosphonium18F-BFPET
Beyond the preview
Go deeper on 18F-TPP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-TPP.